Minerva Neurosciences | NERV - سود قبل از مالیات





سود قبل از مالیات تغییر دادن تاریخ
Acadia Pharmaceuticals USD 26.32M 18.28M 2025-12
Adma Biologics USD 61.59M 14.07M 2025-12
ALKERMES USD 100.74M 4.1M 2025-09
Alterity Therapeutics Limited AUD -4.74M 3.53M 2024-12
AstraZeneca USD 3.24B 117M 2025-09
BioCryst Pharmaceuticals USD 248.02M 235.89M 2025-12
Bristol-Myers Squibb USD 3.11B 1.34B 2025-09
Cipla INR 11.69B 6.85B 2025-12
Clal Biotechnology ILS 86.82M 17.9M 2022-12
Compugen USD 56.84M 63.78M 2025-12
CSL USD 2.61B 1.21B 2025-12
Eli Lilly USD 7.23B 456M 2025-09
Esperion Therapeutics USD 63.67M 95M 2025-12
GlaxoSmithKline GBP 1.23B 1.23B 2025-12
Grifols EUR 257.85M 190.87M 2024-12
Halozyme Therapeutics USD 218.96M 14.02M 2025-09
Ionis Pharmaceuticals USD -228M 99M 2025-12
J&J USD 4.97B 2.53B 2025-12
Merck USD 6.74B 22M 2025-09
Minerva Neurosciences USD 22.51M 30.74M 2024-09
Neurocrine Biosciences USD 239.4M 52.4M 2025-12
Novartis USD 4.64B 445M 2025-12
Novavax USD 17.9M 220.94M 2025-12
Pfizer USD 3.33B 290M 2025-09
Roche Holding CHF 4.79B 3.01B 2025-06
Sanofi EUR -1.16B 5.5B 2025-12
Takeda JPY 133.86B 105.69B 2025-12
Vanda Pharmaceuticals USD -22.92M 16.68M 2024-12